PFE Dec 2026 25.000 call
| Previous Close | 6.20 |
| Open | 6.33 |
| Bid | 6.70 |
| Ask | 6.80 |
| Strike | 25.00 |
| Expire Date | 2026-12-18 |
| Day's Range | 6.33 - 6.75 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 1.44k |
- Investing.com
Midday movers: Intel, Pfizer rise; Apple falls
(Updated - September 16, 2024 11:34 AM EDT)
Business WirePfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia
NEW YORK, September 14, 2024--Pfizer Inc. (NYSE: PFE) today announced its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), met its primary endpoint of change from baseline in body weight compared to placebo in people with cancer cachexia and elevated levels of GDF-15. Cachexia is a common, life-threatening wasting condition that can significantly impact quality of life in affected patients with cancer.ii,iii Results will be presented
Business WirePfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
NEW YORK, September 14, 2024--Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy and safety of BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) for patients with BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC). After an additional 18 months of follow-up, the objective response rate (ORR) and the median duration of response (DoR) as assessed by independent radiology revie
